Related Experiment Video
Updated: Jul 5, 2025
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
13.2K
Biological evaluation of 9-thioansamitocin P3
Natalya I Vasilevich1, Huangyu Jiang1, Haihua Xiao1
1Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China.
Biochemical and Biophysical Research Communications
|January 14, 2024
Summary
9-thioansamitocyn (AP3SH) is a potent maytansinoid derivative effective against various tumors. It induces apoptosis and cell cycle arrest, with favorable metabolic and safety profiles, making it suitable for targeted drug delivery systems.
Area of Science:
- Oncology
- Pharmacology
- Medicinal Chemistry
Background:
- Maytansine derivatives are crucial for targeted tumor delivery due to their high cytotoxicity.
- Previous studies identified the C9 carbinol as essential for maytansinoid potency.
- A 1984 patent described the synthesis and xenograft activity of 9-thioansamitocyn (AP3SH).
Purpose of the Study:
- To comprehensively evaluate the anti-tumor properties of 9-thioansamitocyn (AP3SH).
- To assess the safety and metabolic profile of AP3SH.
- To confirm AP3SH's potential as a cytotoxic payload in drug delivery systems.
Main Methods:
- In vitro antiproliferative assays against 25 tumor cell lines.
- In vivo efficacy studies using a U937 xenograft model.
- Metabolism studies using liver microsomes (CYP isoforms) and safety assessments (hERG inhibition, Ames test).
Main Results:
- AP3SH induces apoptosis and G2/M cell cycle arrest, similar to other maytansinoids.
- Metabolized primarily by CYP3A4, with minimal inhibition of other CYP isoforms and no observed hERG inhibition, CYP induction, or mutagenicity.
- Demonstrated significant antiproliferative activity and tumor growth inhibition in xenograft models.
Conclusions:
- AP3SH exhibits potent anti-tumor activity and a favorable safety profile.
- Its metabolic characteristics and efficacy support its use as a cytotoxic payload in targeted cancer therapies.
- Further development of AP3SH-based drug delivery systems is warranted.
